Egetis Q1 net loss widens to MSEK 94.5; revenue rises 9% to MSEK 13.4

  • Egetis Therapeutics posted revenue of SEK 13.4 million in January–March, up 9% year on year.
  • Net loss widened to SEK 94.5 million; earnings per share held at SEK -0.2.
  • Cash fell to SEK 142.5 million; cash flow for quarter was SEK -72.6 million.
  • FDA accepted Emcitate (tiratricol) NDA for MCT8 deficiency on March 27 with Priority Review; PDUFA date set for Sept. 28, 2026, with no advisory committee currently planned.
  • Directed share issue raised SEK 350 million gross post-quarter; US launch preparations accelerated with a plan for about 25 FTEs by a planned Q4 2026 launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on May 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.